Core Viewpoint - Recently, Zhejiang Shuwen Biotechnology Co., Ltd. announced the completion of nearly 100 million C1 round financing and simultaneously initiated C2 round financing, with funds primarily allocated for the promotion of its globally innovative diagnostic products and new product development in the field of women's health [1] Company Overview - Founded in 2011, Shuwen Biotechnology is headquartered in Deqing, Zhejiang, and focuses on the development, production, sales, and medical testing services of in vitro diagnostic reagents for women's health. The company has established R&D, production, and sales bases in multiple locations, including Hangzhou, Jinhua, Xuancheng, and Berlin, Germany, and is recognized as a national high-tech enterprise [2] - The company has formed long-term partnerships with renowned institutions such as Yale University, the University of Chicago, and BioNTech, accumulating over 100 exclusive diagnostic patents and developing several globally innovative diagnostic products [2] Product and Technology Introduction - Shuwen Biotechnology's product line focuses on two core areas of women's health: maternal and infant medicine and precision diagnosis of breast cancer. The company has launched the world's first home self-test product for pregnant women with preeclampsia, CercaTest RED®, and a urine rapid test product, Wenxian'an®, which significantly improves early detection efficiency of the disease [3] - In breast cancer diagnosis, the company has developed over ten detection products covering the entire disease course, including MammaTyper®, which has been included in Spain's breast cancer treatment guidelines and is used for national-level precision diagnosis in Burkina Faso. The products have received CE certification and are sold in nearly fifty countries globally [4] Financing History - C1 Round Financing (2025): Nearly 100 million, led by Jinchuang Investment, with funds used for global market promotion and new product development [6] - B Round Financing (2021): Nearly 100 million, led by Guolian Investment, aimed at developing innovative products in tumor screening and maternal and reproductive health [6] - A+ Round Financing (2018): Tens of millions of RMB, with investment from Boyi Fund [6] - A Round Financing (2017): Investment from Qianhai Mother Fund [6] - Pre-A Round Financing (2016): Investment from Yuansheng Venture Capital [6] - Angel Round Financing (2016): Investments from Zhonghao Capital, Qianhai Mother Fund, and Yuansheng Venture Capital [6]

Core Viewpoint - Recently, Zhejiang Shuwen Biotechnology Co., Ltd. announced the completion of nearly 100 million C1 round financing and the initiation of C2 round financing, aimed at accelerating the promotion of its innovative diagnostic products and enhancing R&D investment in women's health [1][4]. Group 1: Financing and Investment - The C1 round financing was led by Jinchuang Investment, with existing shareholder Yuansheng Venture Capital continuing to invest [1]. - The funds will be used to promote the company's pioneering diagnostic products in domestic and international markets and to enrich its product pipeline in women's health [1]. Group 2: Product Development and Innovation - Shuwen Biotechnology focuses on the development, production, sales, and medical testing services of in vitro diagnostic reagents, particularly in women's health [1][5]. - The company has developed the world's first home self-test product for preeclampsia, CercaTestRED, and a urine rapid test product, Wenxian'an, which allows pregnant women to screen for preeclampsia at home [2]. - In the breast cancer field, the company has created over ten detection products covering the entire disease course, providing comprehensive solutions for precision medicine, companion diagnostics, and monitoring [2]. Group 3: Global Market Expansion - The company has made significant progress in global market expansion, collaborating with major distributors like Sysmex to promote EU-certified products in nearly 50 countries [3]. - In Europe, the company's subsidiary in Germany promotes its first-in-class products, with MammaTyper included in breast cancer treatment guidelines in Spain and endorsed by the president of Burkina Faso for national use [3]. - Shuwen Biotechnology is also pursuing registrations for innovative home and rapid testing products in the U.S. and EU, as well as entering new drug development and companion diagnostics [3]. Group 4: Future Prospects - The company has initiated a new round of strategic cooperation and financing negotiations to gain more resources and opportunities for global innovation and development in women's health [4]. - Shuwen Biotechnology aims to continue its innovative spirit and launch more high-quality diagnostic products, contributing significantly to women's health [4].